Is Aster DM Health. overvalued or undervalued?
As of July 3, 2025, Aster DM Health is considered very expensive and overvalued with a PE ratio of 16.85, despite strong stock performance, especially when compared to peers like Max Healthcare and Apollo Hospitals.
As of 3 July 2025, the valuation grade for Aster DM Health has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios include a PE ratio of 16.85, an EV to EBITDA of 44.78, and a Price to Book Value of 9.80. Compared to peers, Max Healthcare has a significantly higher PE ratio of 112.13, while Apollo Hospitals is more attractively valued with a PE of 75.12.In light of these metrics, Aster DM Health appears overvalued given its current valuation relative to its earnings and the broader market. The company has shown strong stock performance, with a 1-year return of 86.94% compared to a Sensex return of only 4.07%, which may reflect investor optimism but does not necessarily justify its high valuation.
Mojo Stocks - The Top 1% Picks across Markets
{{col.header}}
Latest
OPEN CALL
CLOSED CALL
{{s[col.key]}}
{{s.change_value}}
{{ s.score.value }} - {{ s.score.call_type }}
{{ s.dot_summary.score }} - {{ s.dot_summary.scoreText }}
{{s[col.key]}}
{{col.extra}}
Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
![]( "Upgrade & View All Insights")
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read